MEK inhibitors (MEKi) have transformed the treatment of tumors such as melanoma and plexiform neurofibroma in neurofibromatosis type 1, but they are frequently associated with dermatological adverse effects that may affect quality of life and treatment adherence. This expert consensus reviews the evidence and provides practical recommendations for the prevention and management of the most common cutaneous toxicities associated with MEKi, including acneiform rash, eczematous dermatitis, xerosis, paronychia, photosensitivity, hair disorders, pruritus, edema, and mucositis. Most of these reactions are mild or moderate and can be controlled through preventive measures, topical or oral treatment, and patient education. Multidisciplinary collaboration between dermatology and oncology is key for early detection, individualized management, and optimization of clinical outcomes, minimizing treatment interruptions and improving the quality of life of patients receiving these therapies.
Prat et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: